Carter Whitfield
Carter reports on session movers and company-specific catalysts, translating guidance changes and contract announcements into what they mean for smaller issuers.
Articles by Carter Whitfield
The ASX Small Cap Everyone Will Be Talking About in 2026: Scalare Partners (ASX: SCP)
27 early-stage tech companies. One ticker. 360% revenue growth lodged with the ASX. Most of the market still hasn't read it.
New Fortress Energy Closes Restructuring That Extinguishes $5.7 Billion of Third-Party Debt, Hives Off Brazil and Leaves Common Holders With 35%
The LNG developer's English restructuring plan took effect Friday. Creditors take the Brazilian business outright, 65% of the surviving company's common stock and preferred equity with a $2.45 billion liquidation preference that ranks ahead of it. Split-adjusted shares are due to resume trading Monday.
InnovAge lifts fiscal 2026 revenue 16% to $989.7m and guides past $1bn
The PACE operator came within $0.7m of GAAP break-even for the year despite $52.4m of accrued litigation loss, and expects census to reach as high as 8,850 participants in fiscal 2027.
Novartis Miss in Myotonic Dystrophy Lands on Dyne Therapeutics, Which Built Its Accelerated-Approval Path on the Same Endpoint
Novartis said Tuesday that its Phase III HARBOR study of del-desiran failed to beat placebo on video hand opening time. Dyne's registrational expansion cohort in the same disease uses that exact measure as its primary endpoint, with topline data guided for the first quarter of 2027.
Pharvaris Reports 83% Reduction in Hereditary Angioedema Attacks Versus Placebo in Pivotal CHAPTER-3 Study
The 85-patient Phase 3 trial of once-daily oral deucrictibant XR met its primary endpoint at p<0.0001 and hit every ranked secondary efficacy endpoint. Pharvaris said it plans to submit a U.S. new drug application in the first half of 2027.
Apogee Enterprises Agrees to Buy Latvia's Groglass for Up to 62.5 Million Euros
The Minneapolis architectural products maker is adding an anti-reflective coated glass specialist to its Performance Surfaces segment. Up to 10 million euros of the price is an earnout tied to three-year financial targets.
Alumis Loses Half Its Market Value After Lupus Trial Misses Overall, Hits in Interferon-High Subgroup
The 408-patient LUMUS study of envudeucitinib failed its primary BICLA endpoint across the whole enrolled population, and Alumis shares fell by more than half in Sept. 1 trading. The company says the interferon-high patients who did respond were unexpectedly under-represented in the trial, a defence that shifts the burden onto a Phase 3 that has not yet been designed.
NewtekOne Resets 2026 EPS Guidance to $1.70-$1.80 as It Stops Selling Its SBA Loans
The lender is keeping the government-guaranteed portions of its SBA 7(a) originations on the balance sheet instead of selling them within about 90 days of origination, swapping upfront gain-on-sale income for interest income earned over years. The new range sits well below the $2.15-$2.55 it published at its January investor day.
argenx Completes $77-a-Share, $2.2 Billion Takeover of Forte Biosciences
About 87 percent of Forte's shares were tendered before the offer expired just after 11:59 p.m. ET on Wednesday, closing an all-cash deal argenx valued at roughly $2.2 billion. argenx says Forte's stock will no longer be listed or traded on the Nasdaq Capital Market.
Aviat Networks Guides Fiscal 2027 Adjusted EBITDA to $50-$55 Million, a Jump It Must Earn Back From Squeezed Gross Margin
The microwave networking supplier posted a GAAP fourth-quarter loss alongside non-GAAP profit, and paired roughly 5% revenue growth guidance with an adjusted EBITDA target about 43% above fiscal 2026 at the midpoint.
Zymeworks Collects a $250 Million Milestone for a Drug It Does Not Sell
Zymeworks said Tuesday that the FDA has cleared two first-line Ziihera regimens in HER2-positive gastroesophageal cancer, triggering a $250 million payment from Jazz Pharmaceuticals. Zymeworks reported $4.6 million of revenue in its most recent quarter.
Expion360 Becomes Expion Energy, Pays $3.425 Million for 3,000 Louisiana Acres and Funds It With $9 Million of 8% Convertible Debentures
The Nasdaq-listed lithium battery maker said on Aug. 24 that it closed the purchase of a drill-ready oil and gas prospect in eastern Louisiana for $3,425,000 in cash, and separately closed an initial $9.0 million of 8% convertible debentures that convert toward common stock at $4.25 a share. The company had $1.54 million of cash at June 30 and its quarterly report disclosed substantial doubt about its ability to continue as a going concern. It reported 953,192 shares outstanding as of June 30, a count that reflects the 1-for-12 reverse split effected on July 21.
Evolution Petroleum Prices $12 Million Stock Sale at $3.25 to Help Fund $16 Million Midland Basin Royalty Purchase
The NYSE American-listed producer priced 3.7 million shares at $3.25 on Aug. 19, with closing expected Aug. 20, to part-fund roughly 3,420 net royalty acres in the Permian. Shares closed at $3.34, down 12.79% on the day.
XTEND's European NATO Contract Is Valued at Up to $15 Million, With About $4.5 Million Secured for the First Year
JFB Construction Holdings said Monday that XTEND, the drone maker it is merging with, signed a multi-year contract with an unnamed European NATO member's defense ministry. The release puts the ceiling at up to approximately $15 million and describes approximately $4.5 million as secured for the first year, with the balance dependent on additional orders and the customer exercising options under the framework agreement. It also moves the expected closing of the merger itself to Sept. 8, a week later than the date given six days earlier.
Anavex Stockholders Vote on the Whole Board Sept. 24. The Cure Period for Its Late 10-Q Could Run to Nov. 16 — If Nasdaq Accepts the Plan.
PVG Asset Management, which says it holds 327,344 Anavex shares, is running six nominees against a slate the company refreshed after a committee of independent directors terminated its chief executive in April for what it classified as Cause under his employment agreement. The company's own 8-K describes an exchange exception that could run to Nov. 16 — almost eight weeks after the meeting — but only if Nasdaq accepts its compliance plan.
Small Caps Take the Record Alone: Russell 2000 Closes at 3,068.42 as the Big Three Fade Into the Weekend
The small-cap benchmark finished Friday at a record 3,068.42 and gained 1.11% on the week, outrunning the S&P 500, Dow and Nasdaq on a session when energy and basic materials led and Treasury yields backed up.
Capricor Jumps as the FDA Agrees to Look at 24-Month Duchenne Data. Agreeing to Look Is Not Approving.
CAPR gave back nearly half its premarket gain by early afternoon; by the company's account the FDA is willing to review an amendment and extend the clock, which says nothing about the outcome.
Globant Trims Its 2026 Outlook as North America Shrinks — and Points at a $52.8 Million AI Line to Explain Why It Isn't Worried
The $1.8 billion NYSE-listed IT services firm held revenue flat at $614.4 million and cut its full-year range for the first time this year. Shares were quoted about 13.6% lower in after-hours trade, against a Thursday close that was up 5.8%.
Blaize cuts its 2026 revenue outlook by two-thirds while CPI Aerostructures posts a profit: Thursday night's small-cap earnings
Three small companies reported after Thursday's close and told three different stories. Blaize took its full-year revenue guidance from $130 million to $40-$43 million, CPI Aerostructures turned a 4.4% gross margin into 22%, and CapsoVision grew revenue 10% while its operating loss widened by more than half.
Fossil Raises Its Outlook While Jack in the Box Pays Up for Debt: Two Small-Cap Consumer Reports Land After Wednesday's Close
Fossil Group lifted full-year guidance on a 490-basis-point gross margin gain even as sales fell, sending shares higher in extended trading. Jack in the Box posted another quarter of negative same-store sales and disclosed the price of the refinancing that fixed its maturity wall.
Cava and H&R Block jump on results while Neurocrine and Performance Food Group slide
Wednesday's mid-cap tape split sharply along earnings lines, with two double-digit gainers on beats and raises and two decliners on a safety report and a narrow revenue miss.
Russell 2000 Edges Higher Ahead of CPI as Small-Business Optimism Hits One-Year High
Small caps outpaced the major averages in Tuesday morning trading, helped by the strongest NFIB optimism reading since last August, as investors braced for Wednesday's inflation report.